Vera Therapeutics, Inc. VERA
30.71 USD +0.46 (+1.52%)
At closeNov 3, 2026, 5:30 PM EST
31.31 +0.60 +1.95%
After hours · Nov 3, 5:30 PM ET
29.90 Day range 31.19
23.05 52-week range 56.05
- YTD
- -39.36%
- 1 year
- +18.39%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 73.79 +140.3% upside
Now 30.71
- Target (low)
- 34.00
- Target (mean)
- 73.79
- Target (high)
- 100.00
Ratings (0m) 14 12 buy · 2 hold · 0 sell
- Strong buy1
- Buy11
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.62 | -1.80 – -1.39 | -1.26 | -28.5% | 3.32M | 0.0% | 8 |
| Next quarter | -1.56 | -2.18 – -1.21 | -1.39 | -12.6% | 15.98M | 0.0% | 8 |
| Current year | -6.27 | -7.23 – -5.77 | -4.66 | -34.5% | 23.12M | 0.0% | 9 |
| Next year | -4.28 | -6.72 – -2.23 | -6.27 | +31.8% | 230.32M | +896.1% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Leerink Partners | Initiated | — | Market Perform |
| Sep 8, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 17, 2026 | Wedbush | Reiterated | Neutral | Neutral |
| Aug 12, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 11, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Jul 8, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 8, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 8, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Jul 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 7, 2026 | B of A Securities | Maintained | Buy | Buy |
| May 15, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Mar 11, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Mar 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 19, 2025 | B of A Securities | Maintained | Buy | Buy |
| Dec 19, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 19, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Dec 11, 2025 | Wedbush | Maintained | Neutral | Neutral |
| Dec 8, 2025 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Dec 5, 2025 | TD Cowen | Maintained | Buy | Buy |
| Nov 10, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 7, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 16, 2025 | B of A Securities | Initiated | — | Buy |
| Aug 7, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 4, 2025 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Jun 2, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Jun 2, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 12, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| May 7, 2025 | Wedbush | Maintained | Neutral | Neutral |
| May 7, 2025 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Mar 4, 2025 | JP Morgan | Maintained | Overweight | Overweight |